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AORTIC STENOSIS (AS)
f 5,621 men and women 65 years of age in the
ardiovascular Health Study (1), 6% progressed from aortic
clerosis to AS over 5 years. Older age, male gender, and
horter height were predictors of progression to AS. Base-
ine C-reactive protein (CRP) concentration was not a
redictor of calcific aortic valve disease at baseline or of its
rogression.
In a retrospective study of 818 patients (2), native AS
rogression could not be predicted by abnormalities in the
even markers of atherosclerotic risk.
High-grade AS valves (57 native valves and 24 biopros-
heses) showed presence of endothelial progenitor cells,
endritic cells, and inflammatory cell markers (3). These
hanges were even more frequently found in bioprosthesis;
ell density was higher in AS. These data point to a systemic
rigin of valvular cells and provide “novel insight” into
echanisms of aortic valve stenosis.
One-third of 216 patients age75 years were denied aortic
alve replacement (AVR) (4). Older age and depressed left
entricular ejection fraction (LVEF) were the characteristics
ost strongly associated with absence of surgery.
In the I-REVIVE trial (5), 16 patients had percutaneous
mplantation of an equine pericardial valve. Three patients
ied early. Among 11 implanted patients, 4 were alive at 6
onths with normal valve function. The ReValving system
sing bovine pericardium for percutaneous valve replace-
ent was initiated (6). A 21-patient feasibility study was
lso initiated.
ITRAL STENOSIS (MS)
ntibiotic prophylaxis: a meta-analysis was undertaken of
0 trials of young adults living on U.S. military bases from
950 to 1961 (7). Antibiotic prophylaxis with a single
njection of intramuscular (IM) penicillin for group A
treptococcal infection was effective for preventing acute
heumatic fever with protective effect of 80% (fixed defect
elative risk [RR] 0.20; 95% confidence interval [CI] 0.11 to
.36); for a need to treat (NTT) number of 60, the marginal
ost was $46.
Catheter balloon commissurotomy (CBC) for MS in 626
atients (8) showed the procedure was effective at a
ollow-up of 6.5  2.5 years in those age 41 years, 42 to
3 years, 54 to 63 years, and in those age 63 years.
In 468 consecutive patients undergoing CBC for MS (9),
he 5-, 10-, and 14-year event-free survival was 94  1 %,“
From the Division of Cardiovascular Medicine, LACUSCMedical Center, Keck
chool of Medicine at University of Southern California, Los Angeles, California.6  9%, and 76  9%. Mitral valve score by echocardio-
ram8 and post-procedure mitral valve area (MVA)2.0
m2 were predictors of restenosis (p  0.0002 and p 
.002, respectively).
ITRAL REGURGITATION (MR)
egenerative (n  20), rheumatic (n  23), and control (n
20) mitral valves were studied by electron microscopy and
mmunochemistry (10). Cellular proliferation and matrix
roduction were shown to be important in the development
f mitral valve disease. The severity of calcification corre-
ated with higher levels of cellular proliferation and matrix
roduction in calcified rheumatic valves as compared to
egenerative mitral valves.
A total of 132 consecutive asymptomatic patients age 55
15 years who had severe “degenerative” MR were seen
rom 1995 to 2002 and were followed until 2004. Mean 
D for follow-up was 62  26 months (11). There were
our deaths: one sudden death in an 80-year-old; three
eaths were unrelated to MR. Thirty-two patients had
urgery for the following indications: symptoms, LVEF
60%, left ventricular end-systolic dimension 45 mm,
ulmonary hypertension (pulmonary artery systolic pressure
50 mmHg), or new onset of atrial fibrillation (AF). There
as no operative mortality. At follow-up, LVEF was
ormal in 28 of 32 patients, the other 4 patients had mitral
alve replacement (MVR) and coronary artery bypass graft
urgery (CABG). Survival of the entire group at two years
as 99  1%, at four years 96  2%, and at six and eight
ears was 91  3%.
A retrospective review of the echocardiography database
evealed 869 patients who had severe MR and normal
VEF (12). The mean age was 68  17 years, 44% were
en, LVEF was 66  7%, diabetes mellitus was present in
9%, hypertension in 65%, and coronary artery disease
CAD) in 39% of patients. Mitral valve surgery was per-
ormed in 44%, and 42% of patients were on a beta-blocker.
se of a beta-blocker was associated with a significantly
educed mortality (p  0.002), which remained unchanged
fter adjusting for age, gender, LVEF, CAD, diabetes,
ypertension, and valve surgery. The independent beneficial
ffects of beta-blockers were seen in patients with CAD and
o CAD and in patients managed both surgically and
onservatively.
The outcome of 1,344 patients operated on between 1980
nd 1995 for severe MR was analyzed by age: 65 years (n
556), 65 to 74 years (n 504), and75 years (n 284).
t baseline, prevalence of severe symptoms, AF, CAD,
ischemic” MR, need for CABG, and creatinine level were
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June 7, 2005:20B–3B ACC 2005 Annual Session Highlightsigher in older versus younger patients (all p  0.002) (13).
ver the time periods of 1980 to 1983, 1984 to 1987, 1988
o 1991, and 1992 to 1995, operative mortality fell progres-
ively, in the two older subgroups from about 23% to 27% to
bout 5%, the incidence of low-output state decreased from
bout 38% to 50% to 10% and the probability of mitral
alve repair increased from approximately 30% to about 80%
o 82% (all p  0.001).
In patients with dilated cardiomyopathy, restrictive mitral
nnuloplasty (RMA) “effectively” restored MR without
ignificant acute changes in baseline hemodynamics and left
entricular systolic function (14).
The EVEREST phase I clinical trial Evalve clip for
ercutaneous edge-to-edge mitral valve repair was per-
ormed in 20 patients, mean age 68 years, of which 75%
ere men (15). A partial clip detached in one patient, and
urgery for MR was performed in two patients. Patients
ere discharged to home at an average time of 1.7 days. At
0 days’ follow-up, the results were “encouraging.” Posterior
yocardial infarction (MI) was produced in six sheep and
as compared to six control sheep. The percutaneous
ransvenous annuloplasty device was evaluated (16). The
R jet area, mitral valve tenting heights, and tenting area in
ll three commissures were significantly greater in chronic
schemic MR than in controls and were significantly re-
uced after coronary sinus-based annuloplasty.
RICUSPID REGURGITATION (TR)
total of 216 patients with functional TR were studied
efore and after tricuspid annuloplasty (17). Residual mod-
rate TR was present in 15% and severe TR in 7.4% of
atients. Multivariate analysis showed that age, tethering
istance, and severity of preoperative TR were predictive of
esidual TR.
Severe symptomatic TR was associated with previous
ermanent pacemaker (PPM) or implantable cardioverter-
efibrillator (ICD) (18). Forty-one patients with a mean age
f 70 years (20 men; 21 women) had a normal tricuspid
alve (TV) apparatus at surgery and 14 had dilated TV. The
PM lead TV perforation was found in 7, entanglement in
V leaflet or chordae in 4, impingement of the TV leaflets
n 16 patients; adherence to the valve was seen in 14
atients. These findings were suspected in only 5 of 41
atients by preoperative transthoracic echocardiography and
of 13 patients in preoperative transesophageal echocar-
iography.
A total of 193 patients underwent MVR for rheumatic
alve disease, of whom 57 also underwent tricuspid annu-
oplasty (TAP) (19). Of 21 patients (10.9%) who developed
R, mitral prosthetic valve function was normal. Severe TR
eveloped in 11 of 35 (28.2%) patients who initially had
evere TR. Despite successful TAP, the severity of TR at
ime of mitral valve surgery was the most important factor
or prediction of severe TR after surgery.
Tricuspid valve replacement provided more complete blimination of TR than did annuloplasty (20). Right ven-
ricular function was reduced after TVR, whereas it was
reserved after annuloplasty.
Fifty-two patients underwent TV repair for functional
R (grade 3) due to annular dilation with three-
imensional ring annuloplasty for TR (Edwards MC3
ystem) (21). At six-month follow-up, TR had a mean
rade of 1.5 (range 0 to 2).
NFECTIVE ENDOCARDITIS (IE)
here was an unchanged pattern of IE. Over a period of 30
ears (1970 to 2000), the population of Olmsted County,
innesota, which consists largely of middle-class whites
ith an “extremely” low prevalence of intravenous (IV)
rug abuse, was evaluated (22). The incidence of IE was
elatively unchanged, and the leading causative organism
as Streptococcus viridans.
In a multicenter, international study of prosthetic valve
ndocarditis (PVE), 355 patients were studied. Surgical
reatment was utilized in 148 patients (41.6%), median time
o surgery was 12 days, and 207 patients (59.4%) were
reated medically (23). In-hospital mortality in the two
roups was 24.3% and 22.7%, respectively (p  0.729), and
as “strongly related” to S. aureus infection and to the
ccurrence of cerebrovascular events with a trend toward
mproved survival with surgery. Surgery for complicated
VE resulted in a similar in-hospital survival rate as for
ncomplicated PVE without surgery.
URGERY
ostoperative AF occurred in 673 of 2,795 patients (24%)
ndergoing CABG (24). The incidence was higher in those
ith hypertension, chronic lung disease, cancer, and in
ubjects in New York Heart Association (NYHA) func-
ional classes III/IV. Those who developed AF had longer
tays in the intensive care unit and in the hospital, and also
ad a higher operative mortality (1.6% vs. 0.7%).
A prospective, randomized trial of four days of IV
miodarone was performed in 120 patients undergoing
ardiac valve surgery (25). At four days, the incidence of AF
as significantly lower in the amiodarone group (10% vs.
6%), but after drug discontinuation it was higher (37% vs.
9%).
A meta-analysis of 12 randomized trials of cardiothoracic
urgery showed prophylactic amiodarone reduced the inci-
ence of postoperative AF with an odds ratio (OR) of 0.47
95% CI 0.39 to 0.57) but the differences of the effects on
troke and total hospital costs were not significantly differ-
nt (26).
A prospective study of 648 patients undergoing cardiac
urgery was performed at 14 VA Medical Centers (27). At
aseline, 29.2% (189 of 648 patients) were depressed; they
ere younger; more were in NYHA functional classes
II/IV, were on preoperative IV nitroglycerin or intra-aortic
alloon pump, and had emergent surgery. Six-month mor-
t
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p  0.03). On multivariable analysis, depressed patients
ad a higher mortality (OR 1.9, 95% CI 1.07 to 3.4; p 
.03).
The 2001 Euro Heart Survey included 5,001 patients;
,231 of these patients underwent valve surgery (28). The
verage age of the patients was 64  13 years, with 43% in
YHA functional class I or II. The operative mortality for
ingle-valve disease was 2.9%, for multiple-valve disease it
as 6.5%, and for redo surgery it was 5.8%. The predictors
f operative mortality were Euroscore (p 0.0001), NYHA
unctional class (p  0.018), and multiple versus single-
alve surgery (p  0.021).
A cohort of 240 consecutive asymptomatic or mildly
ymptomatic patients underwent aortic valve replacement
AVR)  CABG between 1992 and 2004 (29). The
perative mortality for isolated AVR (AS, n  35; aortic
egurgitation [AR], n 82) was 0%; for AVR CABG for
S (n  9) it was 0%; and AR (n  114) it was 1.6%.
In a randomized trial of surgical correction of permanent
F, 51 patients were randomized either to no cryoablation
control), Cox-Maze III surgery, or isolation of pulmonary
eins (IPV) (30). At follow-up of 28.4  14 months, the
ncidence of AF in the control group was 56.3%, whereas
ncidence of sinus rhythm in the IPV group was 88.9% and
n the Maze group it was 84.6%.
Patients who had percutaneous coronary intervention
ollowed by AVR (hybrid procedures; n  20) versus
ABG  AVR (standard; n  114) had a statistically
ignificant higher percentage of women, those who had
revious cardiothoracic surgery, pulmonary hypertension,
nd peripheral vascular disease (31). The 90-day mortality
as similar (5% vs. 4%); 1-year mortality was also similar
6% vs. 9%) as was 1-year MACE incidence was also similar
11% vs. 9%).
ROSTHETIC HEART VALVES
n a prospective study of 89 consecutive patients, mean age
7  13 years, who had prosthetic heart valves, 77.5% of 69
schemic cerebral events were shown by cranial computed
omography to be due to bleeding. The international nor-
alized ratio was 5.0% in seven patients and 1.8 in four
atients (32).
Of 131 explants for structural valve deterioration (SVD)
n bioprosthetic MVR, the only predictor for SVD was
ounger age (p  0.001) (33). Total cholesterol, high-
ensity lipoprotein and low-density lipoprotein cholesterol,
AD, and creatinine levels were not predictors.
Finally, 15 porcine valves of similar annulus size were
tudied in a pulse duplicator at various flow rates to
etermine effect of increasing flow on bioprostheses of
ifferent stiffness (34). As flow rates were increased from 2.0
o 5.75 l/min, peak pressure gradient increased from 16 to
3 mm Hg (p  0.003), the aortic valve area (AVA) ratio
ncreased from 1.16 to 2.10 (p  0.003). However, AVA at.0 to 5.75 l/min was 0.94 versus 0.99 (p  NS) and AVA
t different flow rates ranged from 0.85 to 0.99.
eprint requests and correspondence: Dr. Shahbudin H. Ra-
imtoola, Distinguished Professor, University of Southern Cali-
ornia, 2025 Zonal Avenue, Los Angeles, California 90033.
-mail: rahimtoo@usc.edu.
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